5.60
+0.06
+(1.08%)
At close: January 31 at 4:14:27 PM GMT+1
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Oystein Rekdal Ph.D. | Co-Founder & CEO | 3.6M | -- | -- |
| Mr. Gjest Breistein M.Sc. | Chief Financial Officer | -- | -- | -- |
Lytix Biopharma AS
Sandakerveien 138
Oslo, 0484
Norway
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
Corporate Governance
Lytix Biopharma AS’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
PCIB.OL PCI Biotech Holding ASA
1.2500
+2.12%
CRNA.OL Circio Holding ASA
0.6580
+1.23%
ABTEC.OL Aqua Bio Technology ASA
3.2400
+3.18%
PEG.CO Pharma Equity Group A/S
0.1590
+1.27%
BINV.ST BioInvent International AB (publ)
28.60
+5.73%
FLUI.ST Fluicell AB (publ)
0.0576
+3.60%
ACE.ST Ascelia Pharma AB (publ)
2.9150
+1.92%
BGBIO.OL BerGenBio ASA
7.90
-1.04%
FLUO.ST FluoGuide A/S
50.10
+1.11%
HNSA.ST Hansa Biopharma AB (publ)
34.46
+3.73%